Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
Back to Newsroom
Mentioned in this Article

Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics

Wednesday, July 21, 2021 7:30 AM
Share this article now
Topic:
Company Update

The following press release is no longer available.

 

 

Enzolytics, Inc.
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions